Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
35
OLMA Quote, Financials, Valuation and Earnings
Last price:
$15.07
Seasonality move
:
35.67%
Day range:
$14.62 - $15.12
52-week range:
$2.86 - $36.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.73x
Volume:
904.4K
Avg. volume:
2.1M
1-year change:
352.25%
Market cap:
$1.3B
Revenue:
--
EPS (TTM):
-$1.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals, Inc.
|
-- | -$0.54 | -- | -51.5% | $43.00 |
|
CRVS
Corvus Pharmaceuticals, Inc.
|
-- | -$0.16 | -- | -21.03% | $35.17 |
|
CTMX
CytomX Therapeutics, Inc.
|
$4.7M | -$0.11 | -90.8% | -23% | $13.67 |
|
EYPT
EyePoint Plc
|
$352.8K | -$0.81 | -98.65% | -25.43% | $37.42 |
|
ORIC
Oric Pharmaceuticals, Inc.
|
-- | -$0.32 | -- | -24.41% | $21.00 |
|
PTGX
Protagonist Therapeutics, Inc.
|
$16.3M | -$0.65 | -42.54% | -253.39% | $112.42 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals, Inc.
|
$15.06 | $43.00 | $1.3B | -- | $0.00 | 0% | -- |
|
CRVS
Corvus Pharmaceuticals, Inc.
|
$14.69 | $35.17 | $1.3B | -- | $0.00 | 0% | -- |
|
CTMX
CytomX Therapeutics, Inc.
|
$4.56 | $13.67 | $984.7M | 500.55x | $0.00 | 0% | 8.24x |
|
EYPT
EyePoint Plc
|
$13.40 | $37.42 | $1.1B | -- | $0.00 | 0% | 31.28x |
|
ORIC
Oric Pharmaceuticals, Inc.
|
$8.89 | $21.00 | $1.2B | -- | $0.00 | 0% | -- |
|
PTGX
Protagonist Therapeutics, Inc.
|
$103.78 | $112.42 | $6.6B | 137.53x | $0.00 | 0% | 143.48x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals, Inc.
|
0.87% | 0.768 | 0.21% | 9.76x |
|
CRVS
Corvus Pharmaceuticals, Inc.
|
1.51% | 2.901 | 0.16% | 6.05x |
|
CTMX
CytomX Therapeutics, Inc.
|
4.11% | 13.978 | 0.58% | 2.98x |
|
EYPT
EyePoint Plc
|
6.93% | 2.071 | 1.51% | 8.28x |
|
ORIC
Oric Pharmaceuticals, Inc.
|
1.9% | 3.757 | 0.92% | 13.79x |
|
PTGX
Protagonist Therapeutics, Inc.
|
1.65% | 0.047 | 0.19% | 12.49x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals, Inc.
|
-$187K | -$50.1M | -41.88% | -42.22% | -- | -$38.3M |
|
CRVS
Corvus Pharmaceuticals, Inc.
|
-$26K | -$12.2M | -25.44% | -25.9% | -- | -$9.2M |
|
CTMX
CytomX Therapeutics, Inc.
|
$153K | -$27.9M | -22.55% | -24.75% | -4212.97% | -$23.4M |
|
EYPT
EyePoint Plc
|
-$104K | -$70.3M | -77.2% | -83.61% | -11345.97% | -$66M |
|
ORIC
Oric Pharmaceuticals, Inc.
|
-$320K | -$34.6M | -40.34% | -41.02% | -- | -$22.7M |
|
PTGX
Protagonist Therapeutics, Inc.
|
$7.1M | -$50.4M | -19.44% | -19.76% | -677.09% | -$37.1M |
Olema Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns OLMA or CRVS?
Corvus Pharmaceuticals, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -42.22% beat Corvus Pharmaceuticals, Inc.'s return on equity of -25.9%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals, Inc.-- -$0.50 $482.8M CRVSCorvus Pharmaceuticals, Inc.-- -$0.15 $62.1M -
What do Analysts Say About OLMA or CRVS?
Olema Pharmaceuticals, Inc. has a consensus price target of $43.00, signalling upside risk potential of 185.53%. On the other hand Corvus Pharmaceuticals, Inc. has an analysts' consensus of $35.17 which suggests that it could grow by 139.39%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Corvus Pharmaceuticals, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Corvus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals, Inc.10 1 0 CRVSCorvus Pharmaceuticals, Inc.6 0 0 -
Is OLMA or CRVS More Risky?
Olema Pharmaceuticals, Inc. has a beta of 2.170, which suggesting that the stock is 117.036% more volatile than S&P 500. In comparison Corvus Pharmaceuticals, Inc. has a beta of 0.972, suggesting its less volatile than the S&P 500 by 2.817%.
-
Which is a Better Dividend Stock OLMA or CRVS?
Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corvus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Corvus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or CRVS?
Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Corvus Pharmaceuticals, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$46.1M is lower than Corvus Pharmaceuticals, Inc.'s net income of -$12.3M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Corvus Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus -- for Corvus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals, Inc.-- -- -- -$46.1M CRVSCorvus Pharmaceuticals, Inc.-- -- -- -$12.3M
-
Which has Higher Returns OLMA or CTMX?
CytomX Therapeutics, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of -3998.49%. Olema Pharmaceuticals, Inc.'s return on equity of -42.22% beat CytomX Therapeutics, Inc.'s return on equity of -24.75%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals, Inc.-- -$0.50 $482.8M CTMXCytomX Therapeutics, Inc.23.08% -$0.17 $103.2M -
What do Analysts Say About OLMA or CTMX?
Olema Pharmaceuticals, Inc. has a consensus price target of $43.00, signalling upside risk potential of 185.53%. On the other hand CytomX Therapeutics, Inc. has an analysts' consensus of $13.67 which suggests that it could grow by 199.71%. Given that CytomX Therapeutics, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe CytomX Therapeutics, Inc. is more attractive than Olema Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals, Inc.10 1 0 CTMXCytomX Therapeutics, Inc.6 0 0 -
Is OLMA or CTMX More Risky?
Olema Pharmaceuticals, Inc. has a beta of 2.170, which suggesting that the stock is 117.036% more volatile than S&P 500. In comparison CytomX Therapeutics, Inc. has a beta of 2.487, suggesting its more volatile than the S&P 500 by 148.665%.
-
Which is a Better Dividend Stock OLMA or CTMX?
Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytomX Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CytomX Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or CTMX?
Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than CytomX Therapeutics, Inc. quarterly revenues of $663K. Olema Pharmaceuticals, Inc.'s net income of -$46.1M is lower than CytomX Therapeutics, Inc.'s net income of -$26.5M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while CytomX Therapeutics, Inc.'s PE ratio is 500.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 8.24x for CytomX Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals, Inc.-- -- -- -$46.1M CTMXCytomX Therapeutics, Inc.8.24x 500.55x $663K -$26.5M
-
Which has Higher Returns OLMA or EYPT?
EyePoint Plc has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of -10904.68%. Olema Pharmaceuticals, Inc.'s return on equity of -42.22% beat EyePoint Plc's return on equity of -83.61%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals, Inc.-- -$0.50 $482.8M EYPTEyePoint Plc-16.77% -$0.81 $328.9M -
What do Analysts Say About OLMA or EYPT?
Olema Pharmaceuticals, Inc. has a consensus price target of $43.00, signalling upside risk potential of 185.53%. On the other hand EyePoint Plc has an analysts' consensus of $37.42 which suggests that it could grow by 179.23%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than EyePoint Plc, analysts believe Olema Pharmaceuticals, Inc. is more attractive than EyePoint Plc.
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals, Inc.10 1 0 EYPTEyePoint Plc10 0 0 -
Is OLMA or EYPT More Risky?
Olema Pharmaceuticals, Inc. has a beta of 2.170, which suggesting that the stock is 117.036% more volatile than S&P 500. In comparison EyePoint Plc has a beta of 1.891, suggesting its more volatile than the S&P 500 by 89.146%.
-
Which is a Better Dividend Stock OLMA or EYPT?
Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. EyePoint Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or EYPT?
Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than EyePoint Plc quarterly revenues of $620K. Olema Pharmaceuticals, Inc.'s net income of -$46.1M is higher than EyePoint Plc's net income of -$67.6M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while EyePoint Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 31.28x for EyePoint Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals, Inc.-- -- -- -$46.1M EYPTEyePoint Plc31.28x -- $620K -$67.6M
-
Which has Higher Returns OLMA or ORIC?
Oric Pharmaceuticals, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -42.22% beat Oric Pharmaceuticals, Inc.'s return on equity of -41.02%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals, Inc.-- -$0.50 $482.8M ORICOric Pharmaceuticals, Inc.-- -$0.30 $391.8M -
What do Analysts Say About OLMA or ORIC?
Olema Pharmaceuticals, Inc. has a consensus price target of $43.00, signalling upside risk potential of 185.53%. On the other hand Oric Pharmaceuticals, Inc. has an analysts' consensus of $21.00 which suggests that it could grow by 136.22%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Oric Pharmaceuticals, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Oric Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals, Inc.10 1 0 ORICOric Pharmaceuticals, Inc.12 1 0 -
Is OLMA or ORIC More Risky?
Olema Pharmaceuticals, Inc. has a beta of 2.170, which suggesting that the stock is 117.036% more volatile than S&P 500. In comparison Oric Pharmaceuticals, Inc. has a beta of 1.362, suggesting its more volatile than the S&P 500 by 36.198%.
-
Which is a Better Dividend Stock OLMA or ORIC?
Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oric Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oric Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or ORIC?
Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oric Pharmaceuticals, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$46.1M is lower than Oric Pharmaceuticals, Inc.'s net income of -$30.5M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oric Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus -- for Oric Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals, Inc.-- -- -- -$46.1M ORICOric Pharmaceuticals, Inc.-- -- -- -$30.5M
-
Which has Higher Returns OLMA or PTGX?
Protagonist Therapeutics, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of -596.8%. Olema Pharmaceuticals, Inc.'s return on equity of -42.22% beat Protagonist Therapeutics, Inc.'s return on equity of -19.76%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals, Inc.-- -$0.50 $482.8M PTGXProtagonist Therapeutics, Inc.94.94% -$0.69 $625M -
What do Analysts Say About OLMA or PTGX?
Olema Pharmaceuticals, Inc. has a consensus price target of $43.00, signalling upside risk potential of 185.53%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $112.42 which suggests that it could grow by 8.32%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Protagonist Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals, Inc.10 1 0 PTGXProtagonist Therapeutics, Inc.8 1 0 -
Is OLMA or PTGX More Risky?
Olema Pharmaceuticals, Inc. has a beta of 2.170, which suggesting that the stock is 117.036% more volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.117, suggesting its more volatile than the S&P 500 by 111.747%.
-
Which is a Better Dividend Stock OLMA or PTGX?
Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or PTGX?
Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Protagonist Therapeutics, Inc. quarterly revenues of $7.4M. Olema Pharmaceuticals, Inc.'s net income of -$46.1M is lower than Protagonist Therapeutics, Inc.'s net income of -$44.4M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Protagonist Therapeutics, Inc.'s PE ratio is 137.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 143.48x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals, Inc.-- -- -- -$46.1M PTGXProtagonist Therapeutics, Inc.143.48x 137.53x $7.4M -$44.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
